Clinical Trial: Subcutaneous Aspart Insulin to Treat Diabetic Ketoacidosis (DKA) and Beta-Hydroxybutyrate Testing in DKA
Study Status: Completed
Recruit Status: Completed
Study Type: Interventional
Official Title: Subcutaneous Aspart Insulin and Point of Care Beta Hydroxybutyrate Testing: A New Paradigm for the Management of Diabetic Ketoacidosis
Brief Summary: The purpose of this study is to determine whether insulin administered by a subcutaneous injection is effective in the treatment of a diabetic crisis and to determine if beta-hydroxybutyrate is useful to monitor during treatment of a diabetic crisis.
Detailed Summary:
Sponsor: Rush University Medical Center
Current Primary Outcome:
- Hours to resolution of ketoacidosis as defined as beta-hydroxybutyrate <0.6 [ Time Frame: q 2 hours ]
- Hours to achieve blood glucose less than 200mg/dl [ Time Frame: q 1 hour ]
Original Primary Outcome: Same as current
Current Secondary Outcome:
Original Secondary Outcome:
Information By: Rush University Medical Center
Dates:
Date Received: June 12, 2009
Date Started: January 2005
Date Completion:
Last Updated: August 14, 2012
Last Verified: August 2012
